Probiotic Formula (Bacillus Coagulans) and Toremifene Citrate

• Generic Name: bacillus coagulans / inulin
• Dosage Forms: n.a.
• Other Brand Names: Probiotic Formula, Baciguent, Proferrin-ES

Bacillus coagulans has been used as a probiotic, or "friendly bacteria," to prevent the growth of harmful bacteria in the stomach and intestines. Inulin is fiber that is made from chicory roots. Inulin works in the intestines to help grow probiotic bacteria.

Probiotic Formula (Bacillus Coagulans) is a combination product that has been used in alternative medicine as an aid in treating stomach conditions such as gas pain, constipation, or diarrhea (including viral diarrhea, traveler's diarrhea, or diarrhea caused by taking antibiotic medicine). This medicine has also been used to relieve symptoms of irritable bowel disease, ulcerative colitis, Crohn's disease, or stomach ulcer associated with H. pylori (Helicobacter) infection.

It is not certain whether Probiotic Formula (Bacillus Coagulans) is effective in treating any medical condition. Medicinal use of this product has not been approved by the FDA. This medicine should not be used in place of medication prescribed for you by your doctor.

Probiotic Formula (Bacillus Coagulans) is often sold as an herbal supplement. There are no regulated manufacturing standards in place for many herbal compounds and some marketed supplements have been found to be contaminated with toxic metals or other drugs. Herbal/health supplements should be purchased from a reliable source to minimize the risk of contamination.

Probiotic Formula (Bacillus Coagulans) may also be used for purposes not listed in this product guide.

• Generic Name: toremifene
• Dosage Forms: n.a.
• Other Brand Names: Fareston

Palliative treatment of metastatic breast cancer in postmenopausal women with estrogen-receptor positive or estrogen-receptor unknown tumors (designated an orphan drug by FDA for this use). Not recommended for treatment of estrogen-receptor negative breast tumors. Similar efficacy and toxicity as tamoxifen. Not known whether toremifene offers a therapeutic advantage over tamoxifen for the treatment of advanced breast cancer in eligible patients.

Under investigation for use as adjuvant therapy for early-stage breast cancer in node-positive postmenopausal women. Results from trials to date suggest similar efficacy and toxicity as tamoxifen.

Efficacy in treatment of advanced breast cancer in men not demonstrated.

Because of demonstrated cross-resistance with tamoxifen, usefulness of toremifene as second-line endocrine therapy for treatment of metastatic breast cancer refractory to tamoxifen appears to be limited.

Under investigation as a preventive agent for prostate cancer in men with high-grade prostatic intraepithelial neoplasia and no evidence of prostate cancer.